2.74
-0.08(-2.84%)
Currency In USD
Address
75 Sidney Street
Lexington, MA 02139
United States of America
Phone
857 259 5340
Sector
Healthcare
Industry
Biotechnology
Employees
172
First IPO Date
November 11, 2015
Name | Title | Pay | Year Born |
Dr. Alfred W. Sandrock Jr., M.D., Ph.D. | President, Chief Executive Officer & Director | 1.02M | 1958 |
Ms. Trista Morrison | Chief Corporate Affairs Officer & Chief of Staff to the Chief Executive Officer | 0 | 1977 |
Ms. Jacquelyn Fahey Sandell Esq., J.D. | Chief Legal Officer | 538,162 | 1969 |
Dr. Nathan D. Jorgensen M.B.A., Ph.D. | Chief Financial Officer, Principal Financial Officer & Principal Accounting Officer | 577,748 | 1977 |
Mr. Toby Ferguson M.D., Ph.D. | Chief Medical Officer | 639,706 | 1970 |
Ms. Robin Swartz | Chief Business Officer & Chief Operating Officer | 661,984 | 1971 |
Mr. Todd Carter Ph.D. | Chief Scientific Officer | 0 | 1970 |
Ms. Michelle Quinn Smith | Chief Human Resources Officer | 0 | N/A |
Dr. Krystof Bankiewicz M.D., Ph.D. | Founder | 0 | N/A |
Dr. Mark A. Kay M.D., Ph.D. | Founder | 0 | 1959 |
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia, as well as for spinal muscular atrophy. The company has collaboration and license agreements with Neurocrine Biosciences, Inc., Pfizer Inc., and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.